Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD and Atezolizumab with or without Bevacizumab in Platinum Resistant Ovarian Cancer
NCT02839707Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2017
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of atezolizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by National Cancer Institute. Started Jun 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02839707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02839707.